Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

Study ID
NCT02404935

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

TIME

Trial Summary

National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after start of maintenance therapy.

More informations

Trial Starting Date

Nov 22,2013

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

139